Should I buy or sell Vigil Neuroscience stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vigil Neuroscience in the last twelve months. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VIGL shares. View VIGL analyst ratings or view top-rated stocks .

What is Vigil Neuroscience's stock price target for 2024?

4 brokers have issued 1 year target prices for Vigil Neuroscience's shares. Their VIGL share price targets range from $4.00 to $24.00. On average, they expect the company's share price to reach $17.40 in the next year. This suggests a possible upside of 537.4% from the stock's current price. View analysts price targets for VIGL or view top-rated stocks among Wall Street analysts .

How have VIGL shares performed in 2024?

Vigil Neuroscience's stock was trading at $3.38 at the beginning of the year. Since then, VIGL stock has decreased by 19.2% and is now trading at $2.73. View the best growth stocks for 2024 here .

When is Vigil Neuroscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our VIGL earnings forecast .

How were Vigil Neuroscience's earnings last quarter?

Vigil Neuroscience, Inc. (NASDAQ:VIGL) posted its quarterly earnings data on Tuesday, March, 26th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by $0.01.

When did Vigil Neuroscience IPO?

Vigil Neuroscience (VIGL) raised $112 million in an IPO on Friday, January 7th 2022. The company issued 7,000,000 shares at a price of $15.00-$17.00 per share.

How do I buy shares of Vigil Neuroscience?

Shares of VIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:VIGL

Vigil Neuroscience (VIGL) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Free VIGL Stock Alerts

$2.76

+0.01 (+0.36%)

(As of 03:50 PM ET)

Compare

Today's Range: $2.58
▼
$2.96
50-Day Range: $2.75
▼
$3.48
52-Week Range: $2.53
▼
$11.11

Volume: 51,917 shs
Average Volume: 100,212 shs
Market Capitalization: $101.79 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.40

Get Vigil Neuroscience alerts:

Vigil Neuroscience MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 537.4% Upside
$17.40 Price Target
Short Interest: Bearish
7.06% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.85
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.56) to ($2.45) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.92 out of 5 stars

Medical Sector

562nd out of 918 stocks

Biological Products, Except Diagnostic Industry

87th out of 151 stocks

3.3

Analyst's Opinion

Consensus Rating
Vigil Neuroscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.
Amount of Analyst Coverage
Vigil Neuroscience has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
7.06% of the float of Vigil Neuroscience has been sold short.
Short Interest Ratio / Days to Cover
Vigil Neuroscience has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.
Change versus previous month
Short interest in Vigil Neuroscience has recently decreased by 5.01%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Vigil Neuroscience does not currently pay a dividend.
Dividend Growth
Vigil Neuroscience does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VIGL.

3.2

News and Social Media Coverage

News Sentiment
Vigil Neuroscience has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Vigil Neuroscience this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for VIGL on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
2 people have added Vigil Neuroscience to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vigil Neuroscience insiders have not sold or bought any company stock.
Percentage Held by Insiders
33.45% of the stock of Vigil Neuroscience is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
83.64% of the stock of Vigil Neuroscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Vigil Neuroscience are expected to grow in the coming year, from ($2.56) to ($2.45) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Vigil Neuroscience is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vigil Neuroscience is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Vigil Neuroscience has a P/B Ratio of 0.84. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

About Vigil Neuroscience Stock (NASDAQ:VIGL)

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

VIGL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VIGL Stock News Headlines

April 18, 2024 | markets.businessinsider.com

Vigil Neuroscience Inc: A Strong Buy on Promising ALSP Drug Trial Outcomes and Biomarker Breakthroughs

April 17, 2024 | globenewswire.com

Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

March 29, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Vigil Neuroscience on Promising Clinical Trials and Key Data Readouts

March 27, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL) and Daxor (DXR)

March 27, 2024 | markets.businessinsider.com

Buy Rating Affirmed: Vigil Neuroscience’s Advancing TREM2 Programs and Strong Financial Position

March 26, 2024 | finanznachrichten.de

Vigil Neuroscience, Inc.: Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 26, 2024 | msn.com

Vigil Neuroscience GAAP EPS of -$0.57 in-line

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

March 26, 2024 | benzinga.com

Vigil Neuroscience: Q4 Earnings Insights

March 26, 2024 | investorplace.com

VIGL Stock Earnings: Vigil Neuroscience Misses EPS for Q4 2023

March 26, 2024 | globenewswire.com

Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 24, 2024 | finance.yahoo.com

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

March 20, 2024 | finanznachrichten.de

Vigil Neuroscience, Inc.: Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer

March 20, 2024 | seekingalpha.com

Vigil Neuroscience appoints Kaufmann as Chief Medical Officer

March 20, 2024 | markets.businessinsider.com

Vigil Neuroscience Appoints Petra Kaufmann As CMO

March 20, 2024 | globenewswire.com

Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer

March 16, 2024 | seekingalpha.com

VIGL Vigil Neuroscience, Inc.

March 13, 2024 | globenewswire.com

Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting

March 12, 2024 | globenewswire.com

Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days

March 6, 2024 | globenewswire.com

Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024

February 29, 2024 | globenewswire.com

Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024

February 22, 2024 | benzinga.com

Vigil Neuroscience Stock (NASDAQ:VIGL) Insider Trades

February 7, 2024 | finance.yahoo.com

Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference

January 5, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: AN2 Therapeutics, Inc. (ANTX) and Vigil Neuroscience Inc (VIGL)

January 4, 2024 | finanznachrichten.de

Vigil Neuroscience, Inc.: Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones

January 3, 2024 | finance.yahoo.com

Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones

See More Headlines

Receive VIGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vigil Neuroscience and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/26/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:VIGL
CUSIP: N/A
CIK: 1827087
Web: vigilneuro.com
Phone: 857-254-4445
Fax: N/A
Employees: 69
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $17.40
High Stock Price Target: $24.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +549.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.13)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-82,640,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -57.26%
Return on Assets: -49.50%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.45
Quick Ratio: 10.45

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.24 per share
Price / Book: 0.83

Miscellaneous

Outstanding Shares: 36,880,000
Free Float: 24,547,000
Market Cap: $98.84 million
Optionable: Not Optionable
Beta: 1.77

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Ivana Magovcevic-Liebisch J.D. (Age 57)
Ph.D., President, CEO & Director
Comp: $908.25k
Ms. Jennifer Ziolkowski CPA (Age 50)
Chief Financial Officer
Comp: $617.55k
Sharon Morani
Senior Director of Facilities & Operations
Dr. David Gray Ph.D. (Age 49)
Chief Scientific Officer
Ms. Leah Gibson
Vice President of Investor Relations and Corporate Communications
Mr. Christopher Verni J.D. (Age 49)
General Counsel & Corporate Secretary
April Effort M.B.A.
M.S., VP & Head of Corporate Development
Mr. Evan A. Thackaberry DABT (Age 51)
Ph.D., Senior VP & Head of Early Development
Christian Mirescu Ph.D.
VP & Head of Neuroimmunology
Weeteck Yeo Ph.D.
Senior Vice President of Strategic Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VIGL Stock Analysis - Frequently Asked Questions

Should I buy or sell Vigil Neuroscience stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vigil Neuroscience in the last twelve months. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VIGL shares.
View VIGL analyst ratings or view top-rated stocks.
What is Vigil Neuroscience's stock price target for 2024?: 4 brokers have issued 1 year target prices for Vigil Neuroscience's shares. Their VIGL share price targets range from $4.00 to $24.00. On average, they expect the company's share price to reach $17.40 in the next year. This suggests a possible upside of 537.4% from the stock's current price.
View analysts price targets for VIGL or view top-rated stocks among Wall Street analysts.
How have VIGL shares performed in 2024?: Vigil Neuroscience's stock was trading at $3.38 at the beginning of the year. Since then, VIGL stock has decreased by 19.2% and is now trading at $2.73.
View the best growth stocks for 2024 here.
When is Vigil Neuroscience's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our VIGL earnings forecast.

How were Vigil Neuroscience's earnings last quarter?: Vigil Neuroscience, Inc. (NASDAQ:VIGL) posted its quarterly earnings data on Tuesday, March, 26th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by $0.01.
When did Vigil Neuroscience IPO?: Vigil Neuroscience (VIGL) raised $112 million in an IPO on Friday, January 7th 2022. The company issued 7,000,000 shares at a price of $15.00-$17.00 per share.
How do I buy shares of Vigil Neuroscience?: Shares of VIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VIGL) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Vigil Neuroscience (VIGL) Stock Price, News & Analysis

Vigil Neuroscience MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Vigil Neuroscience Stock (NASDAQ:VIGL)

VIGL Stock Price History

VIGL Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

VIGL Stock Analysis - Frequently Asked Questions

Overall MarketRank^™